Interested in purchasing the book? Order here: https://amzn.to/3R4RWfT Ankit Mahadevia is the founder and CEO of Spero Therapeutics, an organization committed to fighting the threat of infectious disease through the development of novel medicines. Over his career, he has led the formation of nine companies, including Spero, several of which are trading on the Nasdaq exchange and several others acquired by large pharmaceutical organizations. Through these companies, he has raised over $1 billion for the development of novel therapeutics, and built multiple high performing management teams. He and the companies he built have won multiple awards for their culture, including Boston Business Journal’s “Best Places to Work” Award and Glassdoor’s “Top 50 CEOs of 2021” (#15 nationwide). Prior to these roles, Ankit advised on and supported investments in the biotechnology sector as a Venture Partner at Atlas Venture, a Cambridge, MA venture capital firm. He held previous positions at organizations including Genentech, McKinsey & Company, the United States Government Accountability Office, and the U.S. Senate Health, Education, Labor, and Pensions Committee. He has spoken widely on entrepreneurship and leadership, including at Harvard University, Columbia University, Northwestern University, MIT, and the Berkeley Forum. Ankit received his medical degree from the Johns Hopkins University School of Medicine, an MBA from the Wharton School at the University of Pennsylvania, and a BA from Northwestern University. He lives in Chestnut Hill, MA with his wife and two sons.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related